$GMAB

$43.05▲ +7.6% YTD

6 SEC 13D/G filings tracked · Last updated Oct 23, 2026

Filing History

CP $43.05▲ +7.6%Oct 23, 2026 · ThinkSabio Blog

$GMAB Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Surv…

News

GMAB ▼ -1.5% - Genmab A/S

CP $37.23▲ -1.5%Oct 7, 2026 · ThinkSabio Blog

$GMAB H.C. Wainwright raised the firm's price target on Genmab to $50 from $40 and keeps a Buy rating on the shares. The company announced positive re…

News

GMAB ▼ -1.5% - Genmab A/S

CP $37.23▲ -1.5%Oct 7, 2026 · ThinkSabio Blog

$GMAB Guggenheim analyst Michael Schmidt raised the firm's price target on Genmab to $58 from $54 and keeps a Buy rating on the shares, which remain a…

SEC 13D/G

GMAB - Genmab A/S - SEC Filing Update (05-OCT-2026) | ThinkSabio - Stocks Simplified

$38.80▲ 21.90%Oct 6, 2026 · ThinkSabio Blog

$GMAB SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #GMAB Genmab A/S : $38.80 Sector: Healthcare | YTD: 🔼+ 21.90% Th…

News

GMAB ▲ +11.0% - Genmab A/S

CP $38.59▲ +11.0%Oct 5, 2026 · ThinkSabio Blog

$GMAB Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Surviva…

News

GMAB ▲ +0.8% - Genmab A/S

CP $34.81▲ +0.8%Oct 4, 2026 · ThinkSabio Blog

$GMAB Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients…